Top 5 NASDAQ Genetics Stocks (Updated July 2022)

Year-to-date gain: 143.26 percent; market cap: US$258.04 million

Voyager Therapeutics is advancing early stage programs using its proprietary adeno-associated virus (AAV) capsids to develop gene therapies for diseases related to the central nervous system. Its pipeline includes gene therapies for Huntington’s Disease, monogenic ALS, spinal muscular atrophy, GBA1 mutations and HER1+ brain metastases.

Voyager recently inked an agreement to give Novartis (NYSE:NVS) “options to license novel AAV capsids generated from Voyager’s RNA-driven TRACERTM capsid discovery platform for potential use with three undisclosed (central nervous system) targets and options to access capsids for two additional targets to be agreed on in the future.”

This NASDAQ genetics stock spiked to its highest point in 2022 on April 20, hitting C$10.60.

Year-to-date gain: 126.58 percent; market cap: US$212.77 million

ProPhase Labs is a diagnostics and genomics company leveraging its CLIA-accredited lab services to provide whole genome sequencing and research directly to consumers. ProPhase is also building a genomics database for further research. Its subsidiary ProPhase Precision Medicine focuses on genomics testing technologies that help identify inherited disorders, predict disease risk, identify expected drug response and characterize genetic mutations.

ProPhase Labs made two big announcements in June that greatly boosted its share price. First, it partnered with widely recognized healthcare diagnostics companies as part of its plan to significantly expand its in-house clinical testing capabilities. Second, the company announced the formation of a wholly owned subsidiary, ProPhase BioPharma, for the licensing and development of novel drugs, compounds and biotechnology.

This NASDAQ genetics stock spiked to its highest point in 2022 on July 11, hitting C$15.25.

Year-to-date gain: 58.06 percent; market cap: US$343.89 million

Clinical-stage biopharmaceutical company Biomea Fusion’s focus is on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. The company’s proprietary FUSION System is the basis of its pipeline of covalent-binding therapeutic agents targeting cancer and metabolic diseases. These synthetic compounds offer potential advantages over conventional drugs.

This NASDAQ genetics stock spiked to its highest point in 2022 on July 15, hitting C$12.06. The share price increase followed the presentation of positive clinical data showing the potential for the company’s covalent menin inhibitor BMF-219 as an oral, long-acting treatment for Type 2 diabetes; it also came after progress in Biomea's Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor aimed at patients with relapsed/refractory (R/R) multiple myeloma, R/R diffuse large B-cell lymphoma and R/R acute leukemias.

Year-to-date gain: 64.39 percent; market cap: US$834.21 million

Clinical-stage precision oncology company Turning Point Therapeutics has developed a pipeline of investigational precision oncology drug candidates that are being studied across a variety of solid tumors. The company's lead drug candidate is repotrectinib, a next-generation kinase inhibitor targeting the non-small cell lung cancer and advanced solid tumors in adult and pediatric patients.

Turning Point Therapeutics’ biggest news in 2022 is that the company is merging with pharmaceutical giant Bristol Myers Squibb (NYSE:BMY). The deal is expected to close during Q3 of this year.

Shares of Turning Point Therapeutics peaked for 2022 at C$75.38 on July 8.

Year-to-date gain: 53.5 percent; market cap: US$758.27 million

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies targeting rare diseases, including liver diseases.

The company’s LIVMARLI (maralixibat) is an oral solution that is approved in the US for the treatment of cholestatic pruritus in child and adult patients with Alagille syndrome. Mirum has submitted a marketing authorization application to the European Medicines Agency for maralixibat. Additionally, the company has two other late-stage investigational treatments for debilitating liver diseases affecting both children and adults.

In March, Mirum reported net product revenue of US$3.1 million for Q4 2021, which was the first quarter of maralixibat's launch; the company's total revenue for the year came in at US$19.1 million. The firm expects at least US$8 million in maralixibat net product sales in the first quarter of 2022.

Shares of Mirum Pharmaceuticals hit a 2022 peak of C$28.65 on April 11.